Mysoline (Primidone)

Primidone, the active ingredient in Mysoline, is a barbiturate anticonvulsant presented as an oral tablet for systemic use. It is employed to control seizures in epilepsy and to lessen tremor intensity in essential tremor patients, particularly adults, through long‑term therapy.

GNH USA supplies Mysoline as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality‑assurance processes and regulatory approvals across European and global markets. Our distribution network ensures timely delivery and compliance with local import requirements.

Primidone acts as an antiepileptic agent by enhancing GABA‑mediated inhibition, making it useful for several neurological conditions.

Epilepsy: reduces the frequency and severity of generalized and partial seizures, helping patients achieve better seizure control. Essential tremor: diminishes tremor amplitude in adult patients, improving motor function and daily activities. Myoclonic seizures: controls sudden, brief muscle jerks associated with myoclonic epilepsy, contributing to reduced episode frequency. Status epilepticus (adjunct): may be used as an adjunctive therapy in refractory status epilepticus under specialist supervision.

Primidone may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness: sensation of light‑headedness or imbalance. - Drowsiness: increased sleepiness or fatigue. - Nausea: gastrointestinal upset including nausea or vomiting. - Ataxia: impaired coordination and unsteady gait.

Serious or Rare Side Effects: - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Blood dyscrasias: including agranulocytosis or aplastic anemia. - Suicidal thoughts: emergence of depressive symptoms or suicidal ideation. - Respiratory depression: marked slowing of breathing, especially with other CNS depressants. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Severe rash or hypersensitivity: widespread rash, fever, or organ involvement.

When prescribing Primidone, clinicians should consider several safety measures to minimize risk. - Renal function: evaluate baseline kidney function and adjust dosing if impairment is present. - Hepatic function: monitor liver enzymes regularly, as primidone is hepatically metabolized. - Discontinuation: taper gradually to avoid seizure recurrence or withdrawal symptoms. - Elderly patients: start at lower doses and watch for excessive sedation or falls. - Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant. - Store at ambient temperature: keep in original container, protect from moisture and light.

Primidone interacts with several medicines that can alter its effectiveness or increase toxicity.

Major Interactions (Avoid): - Phenobarbital: induces hepatic enzymes, reducing primidone plasma levels and efficacy. - Carbamazepine: increases metabolism, potentially leading to subtherapeutic concentrations. - Valproic acid: may raise primidone levels and heighten risk of central nervous system depression.

Moderate Interactions (Monitor Closely): - Oral contraceptives: primidone can decrease hormonal efficacy, risking unintended pregnancy. - CNS depressants (e.g., benzodiazepines, opioids): additive sedation and respiratory depression. - Alcohol: enhances drowsiness and dizziness, increasing fall risk.